Eikon Therapeutics (EIKN) investor relations material

Executive summary

• Late-stage clinical drug developer with no approved products or product-sales revenue; Q3 2026 net loss was $86.1M as clinical and research spending increased.

• Clinical programs advanced across EIK1001, EIK1003, EIK1004 and EIK1005; EIK1006’s IND was submitted to the FDA in October 2026.

• Cash, cash equivalents and marketable securities totaled $461.7M at September 30, 2026, expected to fund operations into Q1 2028.

Financial highlights

• Q3 operating expenses rose 21% YoY to $90.6M; operating loss was $90.6M versus $74.8M, and net loss attributable to common stockholders was $86.1M versus $71.1M.

• Q3 R&D expense increased 21% to $71.8M and G&A increased 21% to $18.7M; higher clinical activity, professional fees and IT costs contributed to the increases.

• Nine-month operating expenses were $271.3M versus $255.8M; net loss was $257.5M, while net loss attributable to common stockholders was $254.0M after preferred-stock adjustments.

• Nine-month operating cash use was $224.0M versus $146.8M; Q3 and nine-month loss per share were $1.59 and $5.43, respectively, with prior-year comparisons affected by post-IPO shares and preferred-stock adjustments.

Outlook and guidance

• Existing cash, cash equivalents and marketable securities are expected to fund operating expenses and capital expenditures into Q1 2028; the estimate depends on assumptions that may prove inaccurate.

• TeLuRide-006 futility analysis is anticipated in H1 2027; TeLuRide-008 dose-selection interim analysis is expected in H2 2027.

• EIK1003 dose optimization and initial Cohort 1D results, plus EIK1004 combination results, are expected in H2 2027; EIK1005 combination results are expected in H1 2027.

• EIK1006 Phase 1/2 study is planned subject to FDA clearance, with initial safety and efficacy data expected in H2 2027; R&D and G&A spending and substantial losses are expected to continue increasing.